HomeCompareIMRNW vs BTI

IMRNW vs BTI: Dividend Comparison 2026

IMRNW yields 2339.18% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMRNW wins by $43075570633.32M in total portfolio value
10 years
IMRNW
IMRNW
● Live price
2339.18%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43075570633.35M
Annual income
$39,734,102,642,272,360.00
Full IMRNW calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — IMRNW vs BTI

📍 IMRNW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMRNWBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMRNW + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMRNW pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMRNW
Annual income on $10K today (after 15% tax)
$198,830.41/yr
After 10yr DRIP, annual income (after tax)
$33,773,987,245,931,504.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, IMRNW beats the other by $33,773,987,245,929,136.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMRNW + BTI for your $10,000?

IMRNW: 50%BTI: 50%
100% BTI50/50100% IMRNW
Portfolio after 10yr
$21537785316.70M
Annual income
$19,867,051,321,137,572.00/yr
Blended yield
92.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

IMRNW
No analyst data
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMRNW buys
0
BTI buys
0
No recent congressional trades found for IMRNW or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMRNWBTI
Forward yield2339.18%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$43075570633.35M$37.7K
Annual income after 10y$39,734,102,642,272,360.00$2,786.64
Total dividends collected$42841070616.16M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IMRNW vs BTI ($10,000, DRIP)

YearIMRNW PortfolioIMRNW Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$244,618$233,918.13$11,299$598.92+$233.3KIMRNW
2$5,609,462$5,347,721.02$12,794$703.91+$5.60MIMRNW
3$120,610,820$114,608,695.17$14,518$829.07+$120.60MIMRNW
4$2,432,079,455$2,303,025,877.36$16,513$978.64+$2432.06MIMRNW
5$46,004,003,878$43,401,678,861.20$18,827$1,157.84+$46003.99MIMRNW
6$816,480,868,143$767,256,583,993.93$21,518$1,373.12+$816480.85MIMRNW
7$13,600,083,122,647$12,726,448,593,733.79$24,657$1,632.46+$13600083.10MIMRNW
8$212,667,837,578,363$198,115,748,637,130.90$28,329$1,945.74+$212667837.55MIMRNW
9$3,122,867,281,384,664$2,895,312,695,175,815.50$32,637$2,325.33+$3122867281.35MIMRNW
10$43,075,570,633,353,950$39,734,102,642,272,360.00$37,708$2,786.64+$43075570633.32MIMRNW

IMRNW vs BTI: Complete Analysis 2026

IMRNWStock

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers’ diarrhea in the United States, and Travelers’ Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Full IMRNW Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this IMRNW vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMRNW vs SCHDIMRNW vs JEPIIMRNW vs OIMRNW vs KOIMRNW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.